KoBioLabs, Inc (KOSDAQ: 348150)
South Korea
· Delayed Price · Currency is KRW
5,320.00
-130.00 (-2.39%)
Dec 19, 2024, 12:48 PM KST
KoBioLabs Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
Operating Revenue | 61,290 | 33,138 | 11,606 | 2,893 | 4,591 | 576.52 | Upgrade
|
Other Revenue | - | - | -0 | -0 | - | - | Upgrade
|
Revenue | 61,290 | 33,138 | 11,606 | 2,893 | 4,591 | 576.52 | Upgrade
|
Revenue Growth (YoY) | 109.16% | 185.54% | 301.12% | -36.98% | 696.42% | 798.53% | Upgrade
|
Cost of Revenue | 20,114 | 9,429 | 3,627 | 995.01 | 1,956 | 296.9 | Upgrade
|
Gross Profit | 41,176 | 23,709 | 7,979 | 1,898 | 2,636 | 279.62 | Upgrade
|
Selling, General & Admin | 42,124 | 27,321 | 13,675 | 5,580 | 5,894 | 3,153 | Upgrade
|
Research & Development | 9,694 | 14,262 | 14,198 | 12,496 | 8,882 | 4,319 | Upgrade
|
Other Operating Expenses | 198.21 | 173.28 | 163.74 | 25.93 | 87.18 | 95.13 | Upgrade
|
Operating Expenses | 52,508 | 42,167 | 28,270 | 18,236 | 14,981 | 7,632 | Upgrade
|
Operating Income | -11,332 | -18,458 | -20,292 | -16,337 | -12,345 | -7,352 | Upgrade
|
Interest Expense | -770.64 | -1,532 | -1,683 | -152.59 | -708.11 | -776.59 | Upgrade
|
Interest & Investment Income | 2,690 | 3,253 | 2,135 | 499.93 | 402.93 | 231.66 | Upgrade
|
Currency Exchange Gain (Loss) | 1,477 | 653.71 | 36.2 | 113.34 | 242.53 | -17.73 | Upgrade
|
Other Non Operating Income (Expenses) | -928.12 | 1,384 | -3,223 | -498.84 | -42,665 | -36,152 | Upgrade
|
EBT Excluding Unusual Items | -8,864 | -14,700 | -23,026 | -16,376 | -55,072 | -44,067 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | 11.51 | 7.08 | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | -123.43 | - | -15.41 | 0.26 | - | - | Upgrade
|
Other Unusual Items | 447.05 | 16.99 | - | - | - | - | Upgrade
|
Pretax Income | -8,541 | -14,683 | -23,030 | -16,368 | -55,072 | -44,067 | Upgrade
|
Income Tax Expense | 921.66 | 475.14 | 355.52 | -986.27 | - | - | Upgrade
|
Earnings From Continuing Operations | -9,462 | -15,158 | -23,386 | -15,382 | -55,072 | -44,067 | Upgrade
|
Minority Interest in Earnings | -9.3 | 1,305 | 1,464 | - | - | - | Upgrade
|
Net Income | -9,471 | -13,853 | -21,921 | -15,382 | -55,072 | -44,067 | Upgrade
|
Net Income to Common | -9,471 | -13,853 | -21,921 | -15,382 | -55,072 | -44,067 | Upgrade
|
Shares Outstanding (Basic) | 19 | 19 | 17 | 16 | 11 | 7 | Upgrade
|
Shares Outstanding (Diluted) | 19 | 19 | 17 | 16 | 11 | 7 | Upgrade
|
Shares Change (YoY) | 5.32% | 10.30% | 4.68% | 49.69% | 51.75% | 2.60% | Upgrade
|
EPS (Basic) | -496.99 | -747.72 | -1305.15 | -958.62 | -5137.55 | -6238.14 | Upgrade
|
EPS (Diluted) | -497.17 | -748.00 | -1305.15 | -959.00 | -5138.00 | -6238.14 | Upgrade
|
Free Cash Flow | -11,189 | -28,966 | -31,239 | -17,993 | -12,896 | -5,765 | Upgrade
|
Free Cash Flow Per Share | -587.10 | -1563.45 | -1859.89 | -1121.36 | -1202.99 | -816.16 | Upgrade
|
Gross Margin | 67.18% | 71.54% | 68.75% | 65.61% | 57.41% | 48.50% | Upgrade
|
Operating Margin | -18.49% | -55.70% | -174.84% | -564.66% | -268.87% | -1275.22% | Upgrade
|
Profit Margin | -15.45% | -41.80% | -188.89% | -531.63% | -1199.45% | -7643.57% | Upgrade
|
Free Cash Flow Margin | -18.26% | -87.41% | -269.17% | -621.88% | -280.86% | -1000.04% | Upgrade
|
EBITDA | -9,039 | -16,943 | -19,383 | -16,105 | -12,135 | -7,208 | Upgrade
|
EBITDA Margin | -14.75% | -51.13% | -167.02% | - | -264.30% | - | Upgrade
|
D&A For EBITDA | 2,293 | 1,515 | 908.06 | 232.72 | 209.89 | 144.05 | Upgrade
|
EBIT | -11,332 | -18,458 | -20,292 | -16,337 | -12,345 | -7,352 | Upgrade
|
EBIT Margin | -18.49% | -55.70% | -174.84% | - | -268.87% | - | Upgrade
|
Advertising Expenses | - | 7,806 | 3,478 | 717.8 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.